News
A year to remember: Advancements, recognition and transitions
12/20/2024
Catch the 2024 highlights from Providence Cancer Institute in this year-end recap focused on research advancements, caregiver recognition and community engagement.
CAR T cell-therapy, hope and healing: Dean’s story
12/20/2024
Discover how Dean Lookingbill’s battle with lymphoma led him to CAR T-cell therapy at Providence Cancer Institute.
Growing hope
11/19/2024
When a stroke robbed Lauren of her balance, the team on 4K – Providence Acute Rehabilitation Center – helped her regain what she lost with a little help from sunflowers, marigolds and little bugs.
Two clinical trials for solid tumor cancers take different approaches to stop growth
11/22/2024
Two global studies open at Providence Cancer Institute will evaluate combinations of medications to help stop or slow the growth of cancer in solid tumors.
Comprehensive Genomic Profiling leads to better patient outcomes, new joint study says
Real-world data from Providence, Illumina and Microsoft Research finds cancer patients with early genomic testing received better precision treatment, underlines urgency to become standard practice
Leadership change at Providence Cancer Institute, #FINISHCANCER goal remains
11/14/2024
R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed) has accepted the roles of executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute.
2024 SITC Meeting: A glimpse of recent advancements in immunotherapy
11/19/2024
The annual SITC meeting brings together cancer immunotherapy researchers with a goal to advance science, discover breakthroughs and educate the world on cancer immunotherapy.
Harnessing CAR T-cell therapy: A new study for indolent B-cell non-Hodgkin lymphoma
10/30/2024
New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.
New studies test immunotherapy to boost breast cancer treatment and prevent return
10/30/2024
Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.